Fluid Thoughts

The BPI US virtual event will run September 21-24, 2020. The presentation can be viewed On-Demand through the Live Labs section on the virtual portal. A free Exhibit Pass to the event can be requested by visiting https://bit.ly/2FIrLvN. Meissner will be hosting a Solutions Provider booth where visitors can video chat with our team and download product information.

In this 26 minute podcast, the Cell Culture Dish’s Editor, Brandy Sargent, talks with Max Blomberg, Executive Director of Operations, and Andrew Govea, Senior Product Engineer, at Meissner about the challenges of handling bulk drug substance, specifically freeze and thaw, and how the need for scalability, flexibility and a robust approach led to the development of CryoVault™.

The magazine explores the opinions of 14 prominent industry figures centering around Single-Use adoption, advantages/disadvantages, and the future outlook.

A Closer Look at the CryoVault™ Platform for Freeze and Thaw of Bulk Drug Substance (BDS) and Critical Biopharmaceuticals.

At a press conference on Friday, 01FEB2019, Meissner announced that it will expand manufacturing operations by establishing a 100,000 sq.ft. facility in County Mayo, Ireland, creating upwards of 150 jobs over the next 5 years.

Jeff Johnson, Director and New Technology Lead, Global Engineering Solutions, Merck & Co., Inc., delivers a live presentation at INTERPHEX New York on a “Large Scale Single-Use Bulk Drug Substance Freeze and Thaw Platform.” This presentation is an overview of a novel single-use end-to-end solution for freeze, thaw, handling and transport of Bulk Drug Substance. Jeff’s talk touches on design consideration, scalability, stability, and proof of concept.

Join Christian Julien, Meissner Filtration Products and Danielle Werner, Merck, as they discuss the benefits of using the BioPhorum and BPSA’s co-developed SUUR Toolkit in this short video, led by Roberta Toporovski, Bristol-Meyers Squibb.

Max Blomberg, Director of Operations, addresses some of the unique challenges associated with fill and finish operations and how Meissner has worked to mitigate them.

Andrew Govea, Product Engineer, introduces us to this new technology platform and explains the four modular components live at INTERPHEX New York.

Camarillo, CA, January 4th, 2018 – Meissner Filtration products announced that it has acquired PDC Aseptic Filling Systems, a supplier of advanced aseptic filling systems and sealers to the pharmaceutical industry.

This technical bulletin highlights the results of conductivity testing to characterize recirculation mixing performance of single-use systems deployed in Meissner’s QuaDrum® rigid outer containers (ROCs).

Rocker bioreactors, also commonly referred to as wave bioreactors, have been a popular choice for seed train applications and small scale protein production for required working volumes below the 100 L range.

There is a shift toward flexible manufacturing capacity in industry to accommodate situations such as rapid pandemic response, variable production capacity planning for market demand of biosimilars, the desire to manufacture within closer proximity to affected population bases, and personalized medicine.

A panel of pharmaceutical industry experts discusses the advances in bioprocess filtration for improving virus removal and the key to economic large-scale filtration over the last decade.

Meissner was interviewed at their booth during the INTERPHEX New York event to discuss advancements such as the BioLink™ Modular Overmolding Technology, the Saltus® M200 Single-Use Mixing System, and the pharmaceutical industry’s most robust biocontainers – FluoroFlex® PVDF Biocontainers.

A panel of pharmaceutical industry experts delivers advice for first time adopters of single-use technology, and which processes are easiest to transition to disposable technologies.

This article discusses an integrated quality/manufacturing approach to ensure the integrity of single-use biocontainers.